Please login to the form below

Not currently logged in
Email:
Password:

mergers

This page shows the latest mergers news and features for those working in and with pharma, biotech and healthcare.

COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

Fallout from pandemic continues to affect business in myriad ways. The fallout from the COVID-19 pandemic is affecting business in myriad ways, and that includes regulatory reviews of mergers and ... acquisitions. The merger between Pfizer’s Upjohn

Latest news

  • Coronavirus disruption scuppers Curium Pharma sale Coronavirus disruption scuppers Curium Pharma sale

    Paris-headquartered Curium was formed three years ago via the merger of CapVest’s IBA Molecular with the nuclear medicines business of Ireland-listed drugmaker Mallinckrodt. ... The Curium decision comes as other pharma companies waiting for approval

  • AbbVie says Allergan takeover delayed by FTC verdict AbbVie says Allergan takeover delayed by FTC verdict

    The US financial regulator is still carrying outs its antitrust review of the deal, designed to make sure that the merger doesn’t create a combined company with an anti-competitive ... They say the merger with Allergan to create the fourth-largest

  • Menlo slumps as itching drug fails mid-stage trial Menlo slumps as itching drug fails mid-stage trial

    study. The reversal wiped out a steady series of gains for the stock since it announced a merger with Foamix Pharmaceuticals, despite Menlo’s insistence that the failure wouldn’t disrupt ... Foamix CEO David Domzalski joined the conference to call to

  • Tocagen merges with Forte Biosciences after brain cancer fail Tocagen merges with Forte Biosciences after brain cancer fail

    The new company is set to be lead by Forte’s current CEO Paul Wagner, who said of the merger:. ... We are excited about the opportunities created by this merger, as it positions us to become a global leader in inflammatory skin diseases with the

  • AbbVie/Allergan merger faces renewed public opposition despite divestments AbbVie/Allergan merger faces renewed public opposition despite divestments

    Allergan offloaded the investigational drug to AstraZeneca in January in a bid to address any anti-competition concerns surrounding the merger. ... This is not the first public opposition to the AbbVie/Allergan merger – last September, the same groups

More from news
Approximately 110 fully matching, plus 467 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 74 fully matching, plus 49 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 52 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 15 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics